Penn spinout Linnaeus Therapeutics gets key FDA designation
March 11, 2021 at 18:50 PM EST
The company is developing new cancer therapies based on the discoveries of a Penn researcher.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|